Closed system switch units (CSTDs) have been used with hazardous medication for a number of a long time. The aim of this whitepaper is to extend consciousness amongst healthcare professionals, gadget producers, regulators, and pharmaceutical/biotech firms on the potential points round the usage of CSTDs with biologics drug merchandise to permit their knowledgeable use in clinics. Particularly, we focus on the important thing matters associated to the usage of CSTDs with biologics merchandise, together with elements and supplies of building, a breakdown of regulatory, technical, and medical site-related dangers and challenges related to the usage of CSTDs with organic merchandise, gathered from stakeholder dialogue on the IQ Working Group convention, and concerns on present testing necessities and communication methods to drive additional dialog on the suitable use of CSTDs.
Given the technical challenges of utilizing CSTDs with biologics, coupled with the present rules surrounding CSTD approval and correct use, in addition to a necessity for alignment and standardization to allow a constant technique for compatibility testing and communication of incompatibilities, it is strongly recommended that world well being authorities and different stakeholders search to know these points, with a view to alleviate these issues and hold healthcare staff and sufferers secure from hurt.
First Report of Anthracnose of Papaya (Carica papaya L.) Attributable to Colletotrichum siamense in China
Papaya (Carica papaya L.) is a rosaceous plant broadly grown in China, which is economically vital. Anthracnose attributable to Colletotrichum sp. is a crucial postharvest illness, which severely impacts the standard of papaya fruits (Liu et al., 2019). Throughout April 2020, some mature papaya fruits with typical anthracnose signs had been noticed in Fusui, Nanning, Guangxi, China with a mean of 30% illness incidence (DI) and over 60% DI in some orchards. Preliminary signs of those papayas appeared as watery lesions, which turned darkish brown, sunken, with a conidial mass showing on the lesions below humid and heat circumstances.
The illness severity different amongst fruits, with some displaying tiny mild brown spots, and a few ripe fruits presenting brownish, rounded, necrotic and depressed lesions over a part of their floor. Samples from two papaya plantations (107.54°E, 22.38°N) had been collected, and delivered to the laboratory. Symptomatic diseased tissues had been minimize into 5 × 5 mm items, floor sterilized with 2% (v/v) sodium hypochlorite for 1 minute, and rinsed thrice with sterilized water. The items had been then positioned on potato dextrose agar (PDA). After incubation at 25°C in the dead of night for one week, colonies with uniform morphology had been obtained. The aerial mycelium on PDA was white on high facet, and concentric rings of salmon acervuli on the underside.
A gelatinous layer of spores was noticed on a part of PDA plates after 7 days at 28°C. The conidia had been elliptical, aseptate and hyaline (Zhang et al., 2020). The size and width of 60 conidia had been measured for every of the 2 consultant isolates, MG2-1 and MG3-1, and these averaged 13.10 × 5.11 μm and 14.45 × 5.95 μm. DNA was extracted from mycelia of those two isolates with the DNA safe Plant Equipment (TIANGEN, Biotech, China). The interior transcribed spacer (ITS), partial actin (ACT), calmodulin (CAL), chitin synthase (CHS), β-tubulin 2 (TUB2) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) areas had been amplified by PCR and sequenced. The sequences had been deposited into GenBank with accessions MT904003, MT904004, and MT898650 to MT898659.
BLASTN analyses towards the GenBank database confirmed that all of them had over 99% id to the kind pressure of Colletotrichum siamense isolate ICMP 18642 (GenBank accession numbers JX010278, GQ856775, JX009709, GQ856730, JX010410, JX010019) (Weir et al., 2012). A phylogenetic tree primarily based on the mixed ITS, ACT, CAL, CHS, TUB2 and GAPDH sequences utilizing the Neighbor-joining algorithm additionally confirmed that the isolates had been C. siamense. Pathogenicity checks had been carried out on 24 mature, wholesome and surface-sterilized papaya fruits. On 12 papaya fruits, three nicely separated wounded websites had been made for inoculation, and for every wounded web site, six adjoining pinhole wounds had been made in a 5-mm-diameter round space utilizing a sterilized needle. A 10 µl aliquot of 1 × 106 conidia/ml suspension of every of the isolates (MG2-1 and MG3-1) was inoculated into every wound. For every isolate, there have been six replicate fruits.
The management fruits had been inoculated with sterile distilled water. The identical inoculation was utilized to 12 non-wound papaya fruits. Fruits had been then positioned in containers which had been first washed with 75% alcohol and lined with autoclaved filter paper moistened with sterilized distilled water to keep up excessive humidity. The containers had been then sealed and incubated at 28°C. After 10 days, all of the inoculated fruits confirmed signs, whereas the fruits that had been mock inoculated had been with out signs. Koch’s postulates had been fulfilled by re-isolation of C. siamense from diseased fruits. To our data, that is the primary report of C. siamense inflicting anthracnose of papaya in China. This discovering will allow higher management of anthracnose illness attributable to C. siamense on papaya.
Precision Regulation Method: A COVID-19 Triggered Regulatory Drive in South Korea
COVID-19 has triggered numerous adjustments in our on a regular basis lives and the way we conceptualize the capabilities of governments. Some areas require stricter types of regulation whereas others name for deregulation. The problem for the regulatory authorities is to handle these doubtlessly conflicting calls for in regulation and outline coherently their total regulatory rationale. The precision regulation strategy generally is a useful strategy. It’s outlined right here as a streamlined strategy to regulation to ship the proper strategies of regulation for the proper group of individuals on the proper time.
Cellufine PB |
683-986-326 |
JNC America |
50 ml |
Ask for price |
Cellufine PB |
683-986-328 |
JNC America |
500 ml |
Ask for price |
Cellufine PB |
683-986-330 |
JNC America |
5 lt |
Ask for price |
Cellufine PB |
683-986-335 |
JNC America |
10 lt |
Ask for price |
PB antibody |
70R-2192 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Rabbit polyclonal PB antibody raised against the middle region of Pb |
Pseudoproto-Pb |
TBW00844 |
ChemNorm |
unit |
Ask for price |
PB 28 dihydrochloride |
B7107-10 |
ApexBio |
10 mg |
EUR 340.8 |
PB 28 dihydrochloride |
B7107-50 |
ApexBio |
50 mg |
EUR 1245.6 |
PB Blocking Peptide |
33R-2067 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of pb antibody, catalog no. 70R-2192 |
PB Cadherin Antibody |
47938-100ul |
SAB |
100ul |
EUR 302.4 |
PB Cadherin Antibody |
E047938 |
EnoGene |
100μg/100μl |
EUR 255 |
Description: Available in various conjugation types. |
Human PB Plasma |
ABC-TC4012 |
AcceGen |
1 vial |
Ask for price |
|
Description: NPB Plasma is obtained from healthy donors through the COBE Spectra apheresis machine. Between 50 and 150mL of autologous plasma is collected at the same time as the mononuclear cells. |
Human PB Neutrophils |
ABC-TC4289 |
AcceGen |
40M |
Ask for price |
|
Description: Neutrophils compose between 40-75% of white blood cells in the body. They serve as first responders of the inflammatory response of the immune system. |
Human PB Platelets |
ABC-TC4291 |
AcceGen |
1 vial |
Ask for price |
|
Description: Platelets help to stop bleeding at wound sites. When activated, they gather at the site of the wound, change shape and connect to each other to stop the bleeding. |
Human Asthma PB |
ABC-TC4295 |
AcceGen |
1 pack |
Ask for price |
|
Description: <div Asthma is a condition that causes airways to swell and narrow. This creates problems with breathing and can result in coughing, wheezing, shortness of breath, extra mucous production. It can result from an allergic reaction and other hypersensitivities.</div<div <div Specimens available from both adults and pediatric donors. Included types: acute, chronic, severe, bronchial, exercise-induced, allergy-induced, controlled, intermittent, intrinsic, epostic.</div</div<br / |
Human Osteoarthritis PB |
ABC-TC4306 |
AcceGen |
1 pack |
Ask for price |
|
Description: Osteoarthritis is a degenerative joint disease which causes the loss of cartilage, eventually progressing to development of painful bony spurs and cysts in the joints that are affected. |
Human Sjogren's PB |
ABC-TC4314 |
AcceGen |
1 pack |
Ask for price |
|
Description: Sjogrenand#39;s (SHOW-grins) syndrome is a disorder of your immune system identified by its two most common symptoms - dry eyes and a dry mouth. Sjogrenand#39;s syndrome often accompanies other immune system disorders, such as rheumatoid arthritis and lupus. |
Human Scleroderma PB |
ABC-TC4317 |
AcceGen |
1 pack |
Ask for price |
|
Description: Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues - the fibers that provide the framework and support for your body. |
Human COPD PB |
ABC-TC4318 |
AcceGen |
1 pack |
Ask for price |
|
Description: Clinical data may include: Medication (current and historical), Disease Severity, Smoking History, GOLD Stage, Spirometry, Lung function test (FEV, FVC, FEV1%), standard blood chemistry results |
Human PB Leukocytes |
ABC-TC4380 |
AcceGen |
1 vial |
Ask for price |
|
Description: Human Peripheral Blood Leukocyte Primary Cell was derived from Human Peripheral Blood. Cells are positive for CD309, CD19, CD5, CD7, CD9, CD15, CD22, CD45a, CD45 and CD47. |
PB succiniMidyl ester |
T39632-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
Description: PB succiniMidyl ester |
PB succiniMidyl ester |
T39632-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
Description: PB succiniMidyl ester |
PB succiniMidyl ester |
T39632-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
Description: PB succiniMidyl ester |
PB succiniMidyl ester |
T39632-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
Description: PB succiniMidyl ester |
PB succiniMidyl ester |
T39632-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
Description: PB succiniMidyl ester |
PB Cadherin Antibody |
47938 |
SAB |
100ul |
EUR 319 |
PB Cadherin Conjugated Antibody |
C47938 |
SAB |
100ul |
EUR 476.4 |
PB Cadherin Blocking Peptide |
20-abx162098 |
Abbexa |
|
|
|
Anti-PB Cadherin Antibody |
E38A4887 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
Human MS PB Plasma |
ABC-TC3944 |
AcceGen |
1 vial |
Ask for price |
|
Description: Multiple Sclerosis (MS) peripheral blood plasma is obtained by centrifugation of the MS PB. This product has a diminished number of cells and platelets. Fresh MS PB plasma is available upon request. |
Human OA PB Plasma |
ABC-TC4014 |
AcceGen |
1 vial |
Ask for price |
|
Description: Osteoarthritis peripheral blood plasma is obtained by centrifugation of the Osteoarthritis PB. This product has a diminished number of cells and platelets. Fresh Osteoarthritis PB plasma is available upon request. |
Porcine PB Mononuclear Cells |
ABC-TC4034 |
AcceGen |
1 vial |
Ask for price |
|
Description: Porcine Mononuclear Cells are isolated from fresh blood of a mixed breed of pigs (Yorkshire, Hampshire, Poland China). The mononuclear fraction is then further processed to eliminate red blood cells and platelets. |
Human Psoriasis PB Plasma |
ABC-TC4045 |
AcceGen |
1 vial |
Ask for price |
|
Description: Psoriasis peripheral blood plasma is obtained by centrifugation of the Psoriasis PB. This product has a diminished number of cells and platelets. Fresh Psoriasis PB plasma is available upon request. |
Human RA PB Plasma |
ABC-TC4053 |
AcceGen |
1 vial |
Ask for price |
|
Description: Rheumatoid Arthritis (RA) peripheral blood plasma is obtained by centrifugation of the RA PB. This product has a diminished number of cells and platelets. Fresh RA PB plasma is available upon request. |
Human SLE PB Plasma |
ABC-TC4255 |
AcceGen |
1 vial |
Ask for price |
|
Description: Systemic Lupus Erythematosus (SLE) peripheral blood plasma is obtained by centrifugation of the SLE PB. This product has a diminished number of cells and platelets. Fresh SLE PB plasma is available upon request. |
Human Hepatitis B PB |
ABC-TC4298 |
AcceGen |
1 pack |
Ask for price |
|
Description: Hepatitis B is a potentially serious liver disease. The Hepatitis B virus can cause inflammation of the liver, cirrhosis and cancer. Hepatitis B can range from mild to severe. It is one of the most common chronic disease in the world. |
Human Hepatitis C PB |
ABC-TC4300 |
AcceGen |
1 pack |
Ask for price |
|
Description: Hepatitis C (HCV) primarily causes a long-lasting liver disease. It is spread by contact with infected blood. It first became evident in 1974 that a non A/non B hepatitis virus existed. Finally, a test was discovered that could be used to identify the virus in 1989 and from the early 1990s all blood units were screened for HCV. Hepatitis C is more likely than Hepatitis B to cause liver disease. |
Human HIV-1 PB |
ABC-TC4302 |
AcceGen |
1 pack |
Ask for price |
|
Description: HIV-1 is the most common subtype of the lentivirus HIV which infects T helper cells of the immune system. HIV-1 is found worldwide. |
Human HIV-2 PB |
ABC-TC4304 |
AcceGen |
1 pack |
Ask for price |
|
Description: HIV type 2 is a sub species of the lentivirus HIV. HIV-2 has a slower progression rate of the disease, as well as lower rates of transmission compared to HIV-1. Often patients infected with HIV-2 have a low viral load and a slower rate of CD4 cell count decline as compared those infected with HIV-1. |
Human Rheumatoid Arthritis PB |
ABC-TC4308 |
AcceGen |
1 pack |
Ask for price |
|
Description: Characteristics of Rheumatoid Arthritis include joint inflammation, but can also include other areas of the body. It is a systemic illness that can also include inflammation in tissues of the heart, lungs and eyes. |
Human Ulcerative Colitis PB |
ABC-TC4313 |
AcceGen |
1 pack |
Ask for price |
|
Description: Ulcerative Colitis is an immune disease characterized by ulcer formation and inflammation of the large intestine. |
Human Lyme Disease PB |
ABC-TC4315 |
AcceGen |
1 pack |
Ask for price |
|
Description: Lyme disease is caused by four main species of bacteria: Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii and Borrelia garinii bacteria. The most common tick-borne illness in these regions, Lyme disease is transmitted by the bite of an infected black-legged tick, commonly known as a deer tick. |
Rabbit anti-PB Cadherin Antibody |
YLD5967-100ul |
Shanghai YL Biotech |
100 ul |
EUR 320 |
|
Description: Rabbit polyclonal antibody to PB Cadherin |
Rabbit anti-PB Cadherin Antibody |
YLD5967-50ul |
Shanghai YL Biotech |
50 ul |
EUR 200 |
|
Description: Rabbit polyclonal antibody to PB Cadherin |
Human Crohn's Disease PB Plasma |
ABC-TC3392 |
AcceGen |
1 vial |
Ask for price |
|
Description: Crohn's Disease peripheral blood plasma is obtained by centrifugation of the PB. This product has a diminished number of cells and platelets. Fresh Crohn's PB plasma is available upon request. |
Non-human Primate PB Plasma |
ABC-TC3966 |
AcceGen |
1 vial |
Ask for price |
|
Description: Non-human primate-Plasma is processed through centrifugation to diminish cells and platelets. |
Human PB CD8+ T Cells |
ABC-TC4005 |
AcceGen |
1 vial |
Ask for price |
|
Description: NPB-CD8+ Cytotoxic T cells are negatively isolated from Mononuclear Cells using an indirect immunomagnetic CD8+ T cell labeling system. |
Human PB Pan T Cells |
ABC-TC4011 |
AcceGen |
1 vial |
Ask for price |
|
Description: NPB-Pan T Cells are negatively isolated from mononuclear cells using an indirect immunomagnetic Pan-T labeling system. |
Human Ulcerative Colitis PB Plasma |
ABC-TC4268 |
AcceGen |
1 vial |
Ask for price |
|
Description: Ulcerative Colitis peripheral blood plasma is obtained by centrifugation of the PB. This product has a diminished number of cells and platelets. Fresh Ulcerative Colitis PB plasma is available upon request. |
Human Type 2 Diabetes PB |
ABC-TC4312 |
AcceGen |
1 pack |
Ask for price |
|
Description: Non-RI dependent diabetes, or Type 2 Diabetes, is characterized by hyperglycemia that is caused by a combination of RI resistance and the body's inability to compensate by producing more RI. |
Rabbit anti-PB Cadherin Antibody |
DL93887A-100ul |
DL Develop |
100 ul |
EUR 325 |
|
Description: C20orf25; Cadherin-22; Pituitary and brain cadherin; PB-cadherin |
Rabbit anti-PB Cadherin Antibody |
DL93887A-50ul |
DL Develop |
50 ul |
EUR 227.5 |
|
Description: C20orf25; Cadherin-22; Pituitary and brain cadherin; PB-cadherin |
PB-cadherin (T134) polyclonal antibody |
E43S2685 |
EnoGene |
100ul |
EUR 225 |
Description: Available in various conjugation types. |
Human PB CD4+ Helper T Cells |
ABC-TC4001 |
AcceGen |
1 vial |
Ask for price |
|
Description: NPB CD4+ Helper T cells are negatively isolated from mononuclear cells using an indirect immunomagnetic CD4+ T cell labeling system. |
Human Sickle Cell Anemia PB Plasma |
ABC-TC4253 |
AcceGen |
1 vial |
Ask for price |
|
Description: Sickle Cell Anemia (SCA) peripheral blood plasma is obtained by centrifugation of the SCA PB. This product has a diminished number of cells and platelets. Fresh SCA PB plasma is available upon request. |
Human Type I Diabetes PB Plasma |
ABC-TC4264 |
AcceGen |
1 vial |
Ask for price |
|
Description: Type I Diabetes peripheral blood plasma is obtained by centrifugation of the Type I Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type I PB plasma is available upon request. |
Human Type II Diabetes PB Plasma |
ABC-TC4266 |
AcceGen |
1 vial |
Ask for price |
|
Description: Type II Diabetes peripheral blood plasma is obtained by centrifugation of the Type II Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type II PB plasma is available upon request. |
Human Mixed Connected Tissue Disease PB |
ABC-TC4316 |
AcceGen |
1 pack |
Ask for price |
|
Description: Mixed connective tissue disease has signs and symptoms of a combination of disorders - primarily lupus, scleroderma and polymyositis. For this reason, mixed connective tissue disease is sometimes referred to as an overlap disease. |
ARP47877_P050 - pb antibody - middle region (ARP47877_P050) |
ARP47877_P050 |
Aviva Systems Biology |
100ul |
EUR 389 |
|
membranes+electrolyte for o2/pb electr |
SZ02K |
Consort |
ea |
EUR 165.6 |
Pituitary And Brain Cadherin (PB Cadherin) Antibody |
20-abx133389 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
PB-CMV-GreenPuro Scramble Hairpin Control Vector |
PBSI505-000PA-1 |
SBI |
10 ug |
EUR 625 |
Human Frozen/Untouched PB CD19+ B Cells |
ABC-TC3437 |
AcceGen |
1 vial |
Ask for price |
|
Description: Untouched NPB-CD19+ B Cells are negatively isolated from mononuclear cells using an indirect immunomagnetic labeling system. |
Human Multiple Myeloma PB Plasma (Relapsed/Refractory) |
ABC-TC3953 |
AcceGen |
1 vial |
Ask for price |
|
Description: Multiple Myeloma-PB-Plasma is obtained by centrifugation of Multiple Myeloma peripheral blood. Plasma has a diminished number of cells. Multiple Myeloma-PB-Plasma is available in both the newly diagnosed and relapsed/refractory stages. |
Human PB CD4+/CD45RO+ Memory T Cells |
ABC-TC4004 |
AcceGen |
1 vial |
Ask for price |
|
Description: NPB-CD4+ T Cells are negatively isolated from Mononuclear Cells using an indirect immunomagnetic CD4+/CD45RO+ labelling system. |
Human PB Red Blood Cells/Mature Erythrocytes |
ABC-TC4292 |
AcceGen |
1 pack |
Ask for price |
|
Description: Erythrocytes transport oxygen and CO2 to various parts of the body. They are able to do this because they contain Hemoglobin. Additionally, erythrocytes are important in the maintenance of the acid-base balance within the body.<br /Normal PB Red Blood Cells/ mature erythrocytes are collected from healthy donor peripheral blood by density gradien |
Human Acute Lymphoid Leukemia PB Plasma (Relapsed/Refractory) |
ABC-TC3012 |
AcceGen |
1 vial |
Ask for price |
|
Description: Acute Lymphoid Leukemia-PB-Plasma is obtained by centrifugation of Acute Lymphoid Leukemia peripheral blood. This product has a diminished number of cells. Acute Lymphoid Leukemia-Plasma are available in the newly diagnosed and relapsed/refractory stages. |
Human Acute Myeloid Leukemia PB Plasma (Relapsed/Refractory) |
ABC-TC3025 |
AcceGen |
1 vial |
Ask for price |
|
Description: Acute Myeloid Leukemia-PB-Plasma is obtained by centrifugation of Acute Myeloid Leukemia peripheral blood. Acute Myeloid Leukemia-PB-plasma has a diminished number of cells and platelets. Acute Myeloid Leukemia plasma is available in the newly diagnosed and relapsed/refractory stages. |
Human Chronic Lymphoid Leukemia PB Plasma(Relapsed/Refractory) |
ABC-TC3351 |
AcceGen |
1 vial |
Ask for price |
|
Description: Chronic Lymphoid Leukemia-PB Plasma is obtained by centrifugation of the Chronic Lymphoid Leukemia-PB-Mononuclear Cells. Plasma has a diminished number of cells and platelets. Chronic Lymphoid Leukemia plasma is available in untreated and relapsed/refractory stages. |
Human Chronic Myeloid Leukemia PB Plasma (Chronic Phase) |
ABC-TC3364 |
AcceGen |
1 vial |
Ask for price |
|
Description: Chronic Myeloid Leukemia-PB Plasma is obtained by centrifuging Chronic Myeloid Leukemia peripheral blood. Plasma has a diminished number of cells and platelets. Chronic Myeloid Leukemia plasma is available in the chronic phase and accelerated or blast crisis phase. |
Human Frozen/Positively Selected PB CD19+ B Cells |
ABC-TC3434 |
AcceGen |
1 vial |
Ask for price |
|
Description: Positively Selected NPB-CD19+ B Cells are directly isolated from mononuclear cells using immunomagnetic CD19 MicroBeads. |
Human Mantle Cell Lymphoma PB Plasma (Relapsed/Refractory) |
ABC-TC3892 |
AcceGen |
1 vial |
Ask for price |
|
Description: Mantle Cell Lymphoma-Plasma is obtained by centrifugation of blood tissues. Mantle Cell LymphomaPlasma is available in the untreated and relapsed/refractory stages. |
Human Multiple Myeloma PB Plasma (Newly Diagnosed/Untreated) |
ABC-TC3952 |
AcceGen |
1 vial |
Ask for price |
|
Description: Multiple Myeloma-PB-Plasma is obtained by centrifugation of Multiple Myeloma peripheral blood. Plasma has a diminished number of cells. Multiple Myeloma-PB-Plasma is available in both the newly diagnosed and relapsed/refractory stages. |
Human PB CD8+/CD45RA+ Naïve Cytotoxic T Cells |
ABC-TC4006 |
AcceGen |
1 vial |
Ask for price |
|
Description: First, NPB-CD8+ T Cells (CTL) are negatively isolated from Mononuclear Cells using immunomagnetic CD8+ T cell isolation kit. Next, CD45RO MicroBeads are used to deplete the CD45RO+ cell population, leaving a purified CD8+/CD45RA+ Naïve T Cell population. |
PB-CMV-miR-302/367-EF1-GFP iPSC Vector |
PB-MIR302 |
SBI |
10 ug |
EUR 1754 |
Human Acute Lymphoid Leukemia PB Plasma (Newly Diagnosed/Untreated) |
ABC-TC3011 |
AcceGen |
1 vial |
Ask for price |
|
Description: Acute Lymphoid Leukemia-PB-Plasma is obtained by centrifugation of Acute Lymphoid Leukemia peripheral blood. This product has a diminished number of cells. Acute Lymphoid Leukemia-Plasma are available in the newly diagnosed and relapsed/refractory stages. |
Human Acute Myeloid Leukemia PB Plasma (Newly Diagnosed/Untreated) |
ABC-TC3024 |
AcceGen |
1 vial |
Ask for price |
|
Description: Acute Myeloid Leukemia-PB-Plasma is obtained by centrifugation of Acute Myeloid Leukemia peripheral blood. Acute Myeloid Leukemia-PB-plasma has a diminished number of cells and platelets. Acute Myeloid Leukemia plasma is available in the newly diagnosed and relapsed/refractory stages. |
Human Chronic Lymphoid Leukemia PB Plasma (Newly Diagnosed/Untreated) |
ABC-TC3350 |
AcceGen |
1 vial |
Ask for price |
|
Description: Chronic Lymphoid Leukemia-PB Plasma is obtained by centrifugation of the Chronic Lymphoid Leukemia-PB-Mononuclear Cells. Plasma has a diminished number of cells and platelets. Chronic Lymphoid Leukemia plasma is available in untreated and relapsed/refractory stages. |
Human Chronic Myeloid Leukemia PB Plasma (Accelerated/Blast Crisis) |
ABC-TC3363 |
AcceGen |
1 vial |
Ask for price |
|
Description: Chronic Myeloid Leukemia-PB Plasma is obtained by centrifuging Chronic Myeloid Leukemia peripheral blood. Plasma has a diminished number of cells and platelets. Chronic Myeloid Leukemia plasma is available in the chronic phase and accelerated or blast crisis phase. |
Human Frozen/Untouched PB CD19+/CD27+ Memory B cells |
ABC-TC3438 |
AcceGen |
1 vial |
Ask for price |
|
Description: NPB-CD19+/CD27+ memory B cells are negatively isolated from Mononuclear Cells using immunomagnetic isolation system to deplete non-memory B cells. |
Human Frozen/Untouched PB CD19+/IgD+ Naïve B Cells |
ABC-TC3439 |
AcceGen |
1 vial |
Ask for price |
|
Description: NPB-CD19+/IgD+ B cells are negatively isolated from Mononuclear Cells using immunomagnetic isolation system to deplete non-naive B cells. |
Human Mantle Cell Lymphoma PB Plasma (Newly Diagnosed/Untreated) |
ABC-TC3891 |
AcceGen |
1 vial |
Ask for price |
|
Description: Mantle Cell Lymphoma-Plasma is obtained by centrifugation of blood tissues. Mantle Cell LymphomaPlasma is available in the untreated and relapsed/refractory stages. |
Hyal1 (untagged ORF) - Rat hyaluronoglucosaminidase 1 (Hyal1), (10 ug) |
RN211038 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal4 (untagged ORF) - Rat hyaluronoglucosaminidase 4 (Hyal4), (10 ug) |
RN205087 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal2 (untagged ORF) - Rat hyaluronoglucosaminidase 2 (Hyal2), (10 ug) |
RN213034 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal3 (untagged ORF) - Rat hyaluronoglucosaminidase 3 (Hyal3), (10 ug) |
RN208438 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal6 (untagged ORF) - Rat hyaluronoglucosaminidase 6 (Hyal6), (10 ug) |
RN209203 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal5 (untagged ORF) - Rat hyaluronoglucosaminidase 5 (Hyal5), (10 ug) |
RN202125 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal5 (Myc-DDK-tagged ORF) - Rat hyaluronoglucosaminidase 5 (Hyal5), (10 ug) |
RR202125 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal4 (Myc-DDK-tagged ORF) - Rat hyaluronoglucosaminidase 4 (Hyal4), (10 ug) |
RR205087 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal3 (Myc-DDK-tagged ORF) - Rat hyaluronoglucosaminidase 3 (Hyal3), (10 ug) |
RR208438 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal6 (Myc-DDK-tagged ORF) - Rat hyaluronoglucosaminidase 6 (Hyal6), (10 ug) |
RR209203 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal2 (Myc-DDK-tagged ORF) - Rat hyaluronoglucosaminidase 2 (Hyal2), (10 ug) |
RR213034 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Hyal1 (Myc-DDK-tagged ORF) - Rat hyaluronoglucosaminidase 1 (Hyal1), (10 ug) |
RR211038 |
Origene Technologies GmbH |
10 µg |
Ask for price |
Lenti ORF particles, Hyal3 (GFP-tagged) - Mouse hyaluronoglucosaminidase 3 (Hyal3), 200ul, >10^7 TU/mL |
MR206489L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal2 (GFP-tagged) - Mouse hyaluronoglucosaminidase 2 (Hyal2), 200ul, >10^7 TU/mL |
MR225002L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal5 (GFP-tagged) - Mouse hyaluronoglucosaminidase 5 (Hyal5), 200ul, >10^7 TU/mL |
MR221360L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal4 (GFP-tagged) - Mouse hyaluronoglucosaminidase 4 (Hyal4), 200ul, >10^7 TU/mL |
MR220051L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal6 (GFP-tagged) - Mouse hyaluronoglucosaminidase 6 (Hyal6), 200ul, >10^7 TU/mL |
MR215369L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal1 (GFP-tagged) - Mouse hyaluronoglucosaminidase 1 (Hyal1), 200ul, >10^7 TU/mL |
MR207375L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal5 (GFP-tagged ORF) - Rat hyaluronoglucosaminidase 5 (Hyal5), 200ul, >10^7 TU/mL |
RR202125L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal4 (GFP-tagged ORF) - Rat hyaluronoglucosaminidase 4 (Hyal4), 200ul, >10^7 TU/mL |
RR205087L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal3 (GFP-tagged ORF) - Rat hyaluronoglucosaminidase 3 (Hyal3), 200ul, >10^7 TU/mL |
RR208438L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal6 (GFP-tagged ORF) - Rat hyaluronoglucosaminidase 6 (Hyal6), 200ul, >10^7 TU/mL |
RR209203L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal2 (GFP-tagged ORF) - Rat hyaluronoglucosaminidase 2 (Hyal2), 200ul, >10^7 TU/mL |
RR213034L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Lenti ORF particles, Hyal1 (GFP-tagged ORF) - Rat hyaluronoglucosaminidase 1 (Hyal1), 200ul, >10^7 TU/mL |
RR211038L4V |
Origene Technologies GmbH |
200 µl |
Ask for price |
Human Hyaluronidase-1 (HYAL1) |
1-CSB-EP623651HU |
Cusabio |
-
EUR 456.00
-
EUR 256.80
-
EUR 1570.80
-
EUR 672.00
-
EUR 1047.60
-
EUR 314.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human Hyaluronidase-1(HYAL1) expressed in E.coli |
Human Hyaluronidase-2 (HYAL2) |
1-CSB-YP618635HU |
Cusabio |
-
EUR 516.00
-
EUR 280.80
-
EUR 1809.60
-
EUR 770.40
-
EUR 1210.80
-
EUR 349.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human Hyaluronidase-2(HYAL2) expressed in Yeast |
Human Hyaluronidase-1 (HYAL1) |
1-CSB-YP623651HU |
Cusabio |
-
EUR 516.00
-
EUR 280.80
-
EUR 1809.60
-
EUR 770.40
-
EUR 1210.80
-
EUR 349.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Human Hyaluronidase-1(HYAL1) expressed in Yeast |
Lenti ORF clone of Hyal5 (mGFP-tagged ORF) - Rat hyaluronoglucosaminidase 5 (Hyal5), (10 ug) |
RR202125L4 |
Origene Technologies GmbH |
10 µg |
Ask for price |
This problem-solving innovation in regulation triggered by the latest epidemiologic disaster in South Korea demonstrates the emergence of the precision regulation strategy. South Korea has applied streamlined fast-track providers for the biotechnology business to provide check kits swiftly. This text expands the definition of precision regulation from AI regulation literature, and positions the time period as a brand new regulatory rationale, not as a regulatory device, utilizing the case examine from South Korea.